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1 |  INTRODUCTION
Congenital Hyperinsulinism (CHI) is a rare condition that 
presents as severe recurrent neonatal hypoglycemia and can 
lead to irreversible brain injury if not treated promptly. Focal 
CHI is usually restricted to a small area of the pancreas and 
results from inheritance of a paternal ABCC8 or KCNJ11 vari-
ant together with somatic loss of heterozygosity (LOH) of the 
maternal allele at 11p15. In contrast, diffuse CHI is spread 
throughout the pancreas and requires a near-total pancreatec-
tomy. We report the case of a male infant who presented with 
severe hypoglycemia soon after birth and was diagnosed with 
CHI. As he was unresponsive to medical therapy, he underwent 
a subtotal pancreatectomy at 6 weeks of age. At age 16, genetic 
testing revealed a paternally inherited ABCC8 nonsense vari-
ant in the genomic DNA and maternal LOH in the resected 
pancreatic tissue confirming focal CHI. Shortly after transi-
tion to adult endocrinology services, his HbA1c levels started 
to rise and he was diagnosed with diabetes mellitus. Had ge-
netic testing and 18F-DOPA-PET-CT imaging been available 
to guide surgery in 1997, this child would have had a partial 
pancreatectomy to cure his focal CHI thereby mitigating his 
risk of developing insulin-dependent diabetes. At presentation, 
his parents were given a 1:4 recurrence risk which could have 
been reduced to 1:1200 by genetic testing. This case highlights 
major changes in medical management of CHI over a 20-year 
period, which have helped guide surgical options, predict 
prognosis, and improve genetic counseling for these families.
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Abstract
Advances in genomics and 18F-DOPA PET-CT imaging have transformed the man-
agement of infants with Congenital Hyperinsulinism. Preoperative diagnosis of focal 
hyperinsulinism permits limited pancreatectomy with improved clinical outcomes 
while knowledge of the molecular etiology informs genetic counseling and provides 
a more accurate recurrence risk to families.
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Congenital hyperinsulinism (CHI; MIM #256450) is char-
acterized by recurrent severe hypoglycemia due to inappropri-
ate insulin secretion from pancreatic ß-cells. CHI is the most 
frequent cause of hypoglycemia in infancy with an estimated 
incidence of 1:50,000 live births, rising to 1 per 2,500 in pop-
ulations with high rates of consanguinity. 1,2 CHI may be tran-
sient or permanent and inherited in both autosomal recessive 
and dominant forms. The ABCC8 and KCNJ11 genes coding 
for the sulphonylurea receptor (SUR1) and potassium channel 
subunit (Kir6.2), respectively, account for 82% of variants in di-
azoxide-unresponsive patients and 45% of all cases of CHI.3,4 
Both SUR-1 and KIR6.2 are subunits of the ATP-sensitive 
potassium (KATP) channel, which regulates insulin secretion. 
Histologically, two subgroups are apparent; diffuse and focal 
CHI. Both types may be unresponsive to diazoxide treatment 
and are difficult to differentiate clinically. Diffuse CHI is usually 
inherited as an autosomal recessive disorder with abnormal pan-
creatic β-cells throughout the pancreas. Atypical diffuse forms 
of CHI exist due to mosaic uniparental disomy (UPD) in patients 
with dominantly inherited ABCC8 or KCNJ11 gene variants.5 In 
focal CHI, the abnormal β-cells are confined to an isolated le-
sion in the pancreas and minimal surgery can be curative.
There are at least seven genes associated with monogenic 
forms of CHI (ABCC8, KCNJ11, GLUD1, GCK, HADH1, 
HNF4A, and HNF1A) as well as several syndromic genetic 
forms of CHI (eg, Beckwith-Wiedemann, Kabuki, and Turner 
syndromes).6 Focal CHI exhibits a non-Mendelian mode of in-
heritance with KATP channel dysfunction and beta-cell hyper-
plasia that results in CHI.7 In this condition, a paternal ABCC8 
or KCNJ11 germline mutation is inherited in combination with 
somatic loss of heterozygosity (LOH) of a maternally derived 
region within a pancreatic progenitor cell.8 Somatic loss of the 
maternal 11p15 region appears to be the causative factor for 
focal hyperplasia.9 There are at least two maternally expressed 
tumor suppressor genes (H19 and CDKN1C) and a paternally 
expressed insulin-like growth factor II gene (IGF2) in this re-
gion.8 The paternally derived mutation is reduced to somatic 
homozygosity by maternal LOH, and there is an imbalance in 
imprinted genes in the lesion.10 Preoperative use of 18F-Fluorine-
18-L-dihydroxyphenylalanine positron emission-computerized 
tomography (18F-DOPA-PET-CT) scans has proven useful 
for locating focal lesions of islet adenomatosis.11,12 The clin-
ical challenge is to adequately manage patients unresponsive 
to medical therapy as severe persistent hypoglycemia can po-
tentially lead to permanent brain damage and developmental 
delay. This case highlights changes in medical management of 
patients with hyperinsulinism over a 20-year period.
2 |  CASE PRESENTATION
A male infant born at term with macrosomia (4.2  kg, 
SDS  +  1.38) presented with seizures and profound 
neonatal hypoglycemia soon after birth. There was no fam-
ily history of hypoglycemia or maternal diabetes. He had 
a good glycemic response to glucagon and demonstrated 
inappropriately elevated insulin and C-peptide at time 
of hypoglycemia. Free fatty acids and ketones were sup-
pressed, ammonia and cortisol were within normal limits, 
and a metabolic screen was negative. He was diagnosed 
with CHI and started on diazoxide to limit insulin release 
but was unresponsive to both diazoxide and octreotide. As 
a result of his ongoing intractable hypoglycemia, a deci-
sion was made to proceed to surgery. At 6 weeks of age, 
he had a subtotal pancreatectomy (95% removed) in a ter-
tiary pediatric surgical unit. Histological examination re-
vealed multifocal adenomatosis of islet cells, in keeping 
with focal CHI. He initially required insulin for 6 weeks 
postoperatively, but made a full recovery and passed a pro-
vocative fast at 1 year of age. He did not have genetic test-
ing at diagnosis but his parents were given a 1:4 recurrence 
risk for CHI.
3 |  OUTCOME AND FOLLOW-UP
The child had follow-up in the pediatric endocrinology 
service in Cork University Hospital. He had normal devel-
opment, growth, puberty, and academic performance. At 
16 years of age, his HbA1c was 41-44 mmol/mol (Reference 
Interval 20-42), he was asymptomatic, and he was not on any 
medication. At this stage, the proband consented to genetic 
testing to determine the etiology of his CHI and to provide a 
recurrence risk for his family.
Sanger sequencing of the proband revealed a heterozy-
gous nonsense variant, p.(Trp998Ter), (c.2994G > A) in exon 
25 of the ABCC8 gene. Parental analysis showed paternal 
inheritance of the p.(Trp998Ter) variant. A second variant 
was not found in ABCC8 or KCNJ11, and the possibility of a 
focal lesion inherited through maternal LOH was considered. 
Genomic DNA was extracted from the formalin-fixed paraf-
fin-embedded (FFPE) block of resected pancreatic tissue. The 
archival DNA was analyzed for twelve microsatellite markers 
spanning chromosome 11p15.5-11p.15.1, which includes the 
differentially methylated region (IGF2, H19) plus KCNJ11 
and ABCC8 genes. Peripheral leukocyte DNA from the pro-
band and parents was also analyzed for microsatellite markers 
to facilitate haplotyping. Genetic analysis of eight informa-
tive microsatellite markers on chromosome 11, (D11S2071, 
D11S1984, D11S4046, D11S1318, D11S1901, D11S1397, 
D11S1981, and D11S14138) confirmed somatic maternal 
LOH by showing a reduction in the maternal allele in the 
pancreatic tissue compared with peripheral leukocyte DNA 
(Figure 1).
The proband was transitioned to adult endocrinology ser-
vices for ongoing medical follow-up. The clinical concern 
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for the patient at this stage was the high probability of him 
developing diabetes, as there is a higher incidence of dia-
betes (75%-85%) reported in children after pancreatectomy 
for CHI, and he was counseled on this.13 During routine 
surveillance, at 18 years of age, his HbA1c was elevated at 
107 mol/mol, without symptoms, and he was started on in-
sulin therapy.
4 |  DISCUSSION
This case highlights retrospectively how changes in best 
practice and clinical management for CHI over a 20-year pe-
riod (1997-2017) could have provided a different long-term 
outcome for this patient. Children with diffuse CHI require a 
near-total (80%-95%) pancreatectomy and are postoperatively 
F I G U R E  1  Haplotype Mapping of Chromosome 11. Panel A is a graphical representation of the position of twelve microsatellite markers on 
chromosome 11 from 11p15.5 to 11p15.1 shown relative to imprinted loci (IGF2, INS) and candidate gene clusters (KCNJ11, ABCC8). Panel B 
shows the family pedigree and haplotypes based on the results of microsatellite analysis using markers from panel A. Allele sizes for each marker 
are shown in base pair (bp) and colors correspond to the marker locus in panel A. Analysis was performed on leukocyte DNA (germline) in family 
members and on somatic DNA from the proband's archival pancreatic tissue. Eight informative markers showed a deletion of maternal alleles 
(underlined) and revealed loss of heterozygosity in the region spanning the ABCC8 locus
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at risk of persistent hypoglycemia or the development of dia-
betes mellitus in later life.14 Conversely, children with focal 
disease may be cured by resection of their hyperplastic le-
sion and the risk for postoperative diabetes is low.13 Lord 
et al recently reported that 94% of children who had a limited 
pancreatectomy for focal CHI were euglycemic and required 
no further treatment for blood glucose abnormalities.15 Some 
infants with CHI have recognizable clinical features of pre-
natal hyperinsulinism such as fetal overgrowth.16 Hoegsbery 
et al reported hyperinsulinism in a cohort of macrosomic in-
fants from nondiabetic mothers.17 Our patient was born with 
macrosomia and presented with hyperinsulinism soon after 
birth.
The clinical challenge with CHI is to differentiate be-
tween diffuse and focal CHI subtypes as management strat-
egies and clinical outcomes differ significantly. Focal CHI 
lesions are rarely identifiable at time of surgery, and intra-
operative assessment of frozen sections is difficult.18 Prior 
to 2005, pancreatic venous sampling (PVS) and selective 
pancreatic arterial calcium stimulation with hepatic venous 
sampling (ASVS) were used to differentiate between the two 
subtypes.3,19 With the advent of 18F-DOPA PET-CT scans 
in 2005, it became possible to locate focal lesions preop-
eratively and minimize the amount of pancreatic tissue re-
sected..11 The availability of 18F-DOPA diagnostic imaging 
is often limited to specialist centers with expertise in scan 
interpretation and surgical intervention. However, the high 
cure rate (94%) associated with partial pancreatectomy for 
focal CHI justifies referral to these expert centres.15
When CHI was first diagnosed in our patient in 1997, 
18F-DOPA PET-CT scans were not available and the genetics 
of CHI was not well understood. Our patient had a subtotal 
pancreatectomy and histological examination revealed focal 
CHI. In 2013, when he presented again to endocrinology ser-
vices, there was concern about his risk of developing second-
ary diabetes. Diabetes is well recognized in dominant genetic 
forms of CHI such as HNF4A and some ABCC8 variants as a 
long-term complication of pancreatectomy for diffuse CHI.20 
Our patient developed diabetes in adulthood as a consequence 
of the extensive pancreatic surgery he underwent in 1997.
Genetic testing of the proband identified a paternally in-
herited nonsense variant, p.(Trp998Ter), (c.2994G > A) in 
the ABCC8 gene. This variant was previously reported as 
pathogenic in association with persistent hyperinsulinism 
and hypoglycemia of infancy.3 The presence of a monoallelic 
recessive KATP variant is reported to predict focal CHI with 
high sensitivity (97%) and specificity (90%).21 However, an-
other study demonstrated that heterozygosity for a paternal 
ABCC8 or KCNJ11 variant in diazoxide-unresponsiveness 
CHI is not synonymous with a focal lesion.22 Hence, diagno-
sis of focal CHI must be based on clinical features combined 
with the results of genetic testing and 18F-DOPA PET-CT 
scanning.15
Microsatellite analysis of the resected pancreatic tissue 
of the proband showed maternal LOH in the region spanning 
chromosome 11p15.5-11p15.1, which includes the ABCC8 
locus. The inheritance of a paternal ABCC8 nonsense muta-
tion and somatic LOH of the maternal allele unmasked a re-
cessive disorder and confirmed focal disease (see Figure 1). 
The deleted region on chromosome 11 contains two clus-
ters of candidate genes. The first cluster at 11p15.5 is an 
imprinted domain containing maternally expressed genes 
H19 and CDKN1C (p57KIP2) and the paternally expressed 
IGF2 gene.23,24 The second cluster at 11p15.1 contains the 
KCNJ11 (SUR1) and ABCC8 (KIR6.2) genes that code for 
subunits of the β cell KATP channel. KCNJ11 and ABCC8 
are not known imprinted genes but lie next to an imprinted 
domain and could be involved in epigenetic control.3 Normal 
cell growth requires a balance between H19 (tumor suppres-
sor) and IGF2 (autocrine growth factor). In our case, loss of 
H19 expression with upregulation of IGF2 caused β cell pro-
liferation and the reduction to homozygosity of the ABCC8 
variant led to focal hyperinsulinism. The size of the focal 
lesion is dependent on the stage when LOH occurs, which 
most likely occurs in the late embryonic or early neonatal 
period.8,25
Focal CHI results from a constitutional ABCC8 pater-
nal mutation in combination with somatic loss of mater-
nal 11p15.5-15.1 or a “second hit phenomenon”.26-28 Prior 
knowledge of the genetic etiology can guide surgical proce-
dures, inform prognosis and aid genetic counseling.29 The 
availability of rapid gene sequencing and 18F-DOPA PET-CT 
imaging is critical to the management of diazoxide-unrespon-
sive patients.30 Recent advances in genomics have facilitated 
earlier diagnosis with a transition from single-gene testing 
by Sanger sequencing to comprehensive genomic testing 
by next-generation sequencing. This has improved diagnos-
tic yield with increased detection of deletions and mosaic 
variants.18
When CHI was first diagnosed in our patient in 1997, ge-
netic testing was not available and the parents were given a 
1:4 recurrence risk. Following genetic testing in 2013, the 
family's recurrence risk was lowered substantially. The pro-
band has four younger siblings and their prior risk of inher-
iting the paternal mutation is 1:2. When this is combined 
with the risk of a sporadic event in the pancreas giving rise to 
maternal LOH, reported as 1:600, their prior risk of inherit-
ing CHI is 1:1200.31 Genetic counseling is recommended for 
families of children with focal CHI as although, the sporadic 
event leading to maternal LOH is a rare event during fetal de-
velopment, there is one reported case of focal CHI occurring 
in two siblings.31
CHI is a heterogenous disorder with high morbidity and 
limited therapeutic options. Knowledge of the underlying 
genetic etiology is key as potassium channel mutations 
are often refractory to medical management but minimum 
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pancreatic resection can be curative. Although treatment 
for CHI has improved over the last decade, the risk of ad-
verse neurodevelopment remains high with studies quoting 
incidence frequencies between 26% and 48%.20,32 Kaiser 
et al report early transient newborn hypoglycemia associ-
ated with poor academic performance as evidenced by lower 
achievement test scores at 10 years of age.33 Consequently, 
reliable newborn screening programs are urgently needed 
for the early detection of CHI to prevent irreversible brain 
injury.
The strength of our case is its educational value from a 
patient management perspective. It highlights the molecular 
mechanisms underlying CHI while focusing on the merits 
of genomic testing and diagnostic imaging to guide surgical 
management, inform genetic counseling, and improve clini-
cal outcomes. Had these modalities been available at the time 
of our patient's presentation, there is no doubt his medical 
management would have been different. He would have had a 
partial pancreatectomy for his focal CHI, and this would have 
likely mitigated against his development of iatrogenic diabe-
tes. For older cases which have not previously been worked 
up from a genetic perspective, we would recommend pursing 
archival tissue to fully elucidate the genotype. This case high-
lights the need to develop clinical guidelines for retrospective 
investigation of older CHI cases so that future risks to off-
spring may be calculated.
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